Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NMT1 | P30419 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1579503 | 0.93 | NCF1 (0.60) | NCF1SIGMAR1CHRM1ACHERAD52 | |
| SCHEMBL11164665 | 0.89 | NCF1 (0.56) | NCF1SIGMAR1ACHEGNAI3GNAO1 | |
| SCHEMBL11157613 | 0.86 | NCF1 (0.54) | NCF1SIGMAR1ACHEGNAI3GNAO1 | |
| SCHEMBL41970 | 0.84 | NCF1 (0.65) | NCF1SIGMAR1CHRM1ACHEGNAI3 | |
| SCHEMBL245769 | 0.84 | NCF1 (0.56) | NCF1SIGMAR1ACHEGNAI3GNAO1 | |
| SCHEMBL28478842 | 0.83 | NCF1 (0.52) | NCF1SIGMAR1CHRM1ACHERAD52 | |
| SCHEMBL23718143 | 0.82 | NCF1 (0.44) | NCF1SIGMAR1CHRM1ACHERAD52 | |
| SCHEMBL7345202 | 0.80 | GNAO1 (0.56) | NCF1CHRM1ACHEGNAI3GNAO1 | |
| SCHEMBL6121353 | 0.79 | SIGMAR1 (0.50) | NCF1SIGMAR1CHRM1RAD52ALDH1A1 | |
| SCHEMBL13598964 | 0.78 | GNAO1 (0.58) | NCF1CHRM1ACHEGNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371548-A1 | HYALURONIC ACID DERIVATIVE MODIFIED WITH POLYETHYLENE GLYCOL | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-12-02 | — | — | US | disclosed |
| EP-3712181-A1 | HYALURONIC ACID DERIVATIVE MODIFIED WITH POLY(ETHYLENE GLYCOL) | Chugai Seiyaku Kabushiki Kaisha (JP) | 2020-09-23 | — | — | EP | disclosed |
| US-20190142959-A1 | HYALURONIC ACID DERIVATIVES INTO WHICH CATIONIC AND HYDROPHOBIC GROUPS ARE INTRODUCED | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2019-05-16 | — | — | US | disclosed |
| EP-3456745-A1 | HYALURONIC ACID DERIVATIVE HAVING CATIONIC GROUP AND HYDROPHOBIC GROUP INTRODUCED THEREIN | Chugai Seiyaku Kabushiki Kaisha (JP) | 2019-03-20 | — | — | EP | disclosed |
| WO-2017195880-A1 | HYALURONIC ACID DERIVATIVE HAVING CATIONIC GROUP AND HYDROPHOBIC GROUP INTRODUCED THEREIN | 中外製薬株式会社 | 2017-11-16 | — | — | WO | disclosed |
| EP-1481966-B1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2011-07-20 | — | — | EP | disclosed |
| EP-2004188-B1 | BENZOIMIDAZOL-2-YL PYRIDINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-01 | — | — | EP | disclosed |
| US-7589087-B2 | Benzoimidazol-2-yl pyridines as modulators of the histamine H4receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-09-15 | — | — | US | disclosed |
| EP-2004188-A4 | BENZOIMIDAZOL-2-YL PYRIDINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-22 | — | — | EP | disclosed |
| EP-2004188-A2 | BENZOIMIDAZOL-2-YL PYRIDINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007117400-A2 | BENZOIMIDAZOL-2-YL PYRIDINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-18 | — | — | WO | disclosed |
| US-20070232616-A1 | Benzoimidazol-2-yl pyridines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371548-A1 | HYALURONIC ACID DERIVATIVE MODIFIED WITH POLYETHYLENE GLYCOL | CD44, F12, HPSE | NCF1 1432/4885SIGMAR1 3577/4885CHRM1 4013/4885 |
| US-20070232616-A1 | Benzoimidazol-2-yl pyridines as modulators of the histamine H4 receptor | HRH4, HRH3, HRH2 | NCF1 1170/4885SIGMAR1 1574/4885CHRM1 166/4885 |
| US-20190142959-A1 | HYALURONIC ACID DERIVATIVES INTO WHICH CATIONIC AND HYDROPHOBIC GROUPS ARE INTRODUCED | CD44, MUC1, FUT5 | NCF1 724/4885SIGMAR1 3062/4885CHRM1 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.